Champions Biotechnology Inc.

Champions Biotechnology Inc.'s preclinical screening technology uses xenografts that it creates by implanting primary human cancer tumors into immune-deficient mice. The tumor cells are never passaged in cell tissue culture and therefore maintain the fundamental genotypic features of the original cancer because the risk of mutations through successive generations in culture is eliminated. The company has signed preclinical screening deals with a number of partners and it's also building its own therapeutic pipeline.